Show results for
Refine by
Antigen Targeting Equipment & Supplies In Morocco
51 equipment items found
Manufactured by:Eutilex Co.,Ltd. based inSeoul, SOUTH KOREA
4-1BB mAb-based, tumor antigen targeting bispecific ...
Manufactured by:Ardigen based inKraków, POLAND
Quick solution for effective immune responses in clinical trials; We have created an Artificial Intelligence platform dedicated to being a part of the therapeutic cancer vaccine development. The ArdImmune Vax platform uses sequencing data to generate and prioritize antigen targets for cancer vaccines and T-cell ...
Manufactured by:Beijing Meizheng Bio-Tech Co., Ltd based inYanqing District, CHINA
Purification of GST-tagged proteins can be performed under very mild conditions, which preserves the function and antigenicity of the target ...
Manufactured by:Lorne Laboratories Limited based inBerkshire, UNITED KINGDOM
Lorne Stained Febrile Antigens are products designed for the identification of pathogens such as Salmonella, Rickettsiae, and Brucellae through agglutination tests. The antigen suspensions comprise killed bacteria stained for improved visibility in these tests. Blue stained antigens target the somatic 'O' ...
Manufactured by:SYnAbs S.A. based inGosselies, BELGIUM
Transmembrane proteins are probably the most complex and challenging antigens to target with monoclonal antibodies. Indeed, despite their strong presence in the animal kingdom and their implications in many cellular mechanisms, they remain very difficult to access due to intrinsic properties. ...
Manufactured by:PharmAbcine Inc. based inYuseong-gu, SOUTH KOREA
PharmAbcine’s fully human antibody library provides the diversity of antibody candidates for target antigens, ensuring highest success rates of developing therapeutic antibodies for various indications. Our unique and diverse antibody repertoires are constructed by recombination of V gene segments and DJ gene segments in human B-cell derived antibody heavy ...
by:AdAlta Limited based inBundoora, AUSTRALIA
Under the Collaboration Agreement, AdAlta will discover and optimise panels of i-bodies that bind to designated solid tumour antigen targets, from which Carina will generate CAR-T cells and identify optimal CAR-T product candidates including bi-specific CAR-T products. Carina and AdAlta will jointly fund pre-clinical proof of concept studies in mouse tumour ...
Manufactured by:INOVIO Pharmaceuticals based inPlymouth Meeting, PENNSYLVANIA (USA)
SynCon uses a proprietary computer algorithm that has been designed to identify and optimize the DNA sequence of the target antigen, whether it is a virus or a tumor. Once this sequence has been determined, the DNA is synthesized or reorganized, and manufacturing can ...
Manufactured by:TC BioPharm based inHolytown, UNITED KINGDOM
TCB004 is a gamma delta CAR-T product for the treatment of AML redirected against an undisclosed target antigen. The co-stim CAR structure on TCB004 prevents toxicity against healthy cells and is ideally suited for targeting AML where finding a target ubiquitously and exclusively presented on diseased cells has so far proved ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Cergutuzumab amunaleukin (CEA-IL2v) is a monomeric carcinoembryonic antigen (CEA)-targeted IL-2 variant-based immunocytokine. Cergutuzumab amunaleukin has immunostimulating and antineoplastic ...
by:Taiwan Liposome Company, Ltd. (TLC) based inNangang Distric, TAIWAN
TLC is using antibodies and antibody fragments attached to lipid encapsulated drugs to develop more effective therapies in oncology. These antibody-linked nanomedicines actively target specific tissues using binding interactions between a specific antibody and a target antigen on the surface of a particular cell type. Compared with passively ...
Manufactured by:INOVIO Pharmaceuticals based inPlymouth Meeting, PENNSYLVANIA (USA)
INOVIO’s DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using one of INOVIO’s proprietary hand-held CELLECTRA smart devices. Once inside the cell, the DNA plasmids enable the cell to produce the targeted antigen. The antigen is processed naturally in the cell and triggers the desired T ...
Manufactured by:Blue Earth Diagnostics based inOxford, UNITED KINGDOM
Therapeutic nuclear medicine, also known as theranostics, combines tumour targeting with a therapeutic dose of radiation. Tumour targeting allows radiopharmaceuticals to selectively target cells associated with disease due to the affinity between the drug and certain receptors expressed by the relevant cells. The targeting ...
Manufactured by:The Menarini Group based inFlorence, ITALY
MEN1309 is an antibody-drug conjugate (ADC) constituted by a fully human IgG1 antibody conjugated through a cleavable linker to a cytotoxic agent (a maytansin derivative, DM4), responsible for its antitumor activity. The target antigen, CD205, is highly expressed in a wide range of both solid and hematological cancer cells. Once MEN1309 binds its ...
by:Kephera Diagnostics, LLC based inFramingham, MASSACHUSETTS (USA)
Our proprietary assay technology is based on principles of particle interaction combined with a simple device, which together enable rapid detection of specific antibodies or antigens associated with the target pathogen. The broadly enabling technology is applicable to a wide range of disease targets and applications. Kephera’s expertise ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
Immunotherapeutic cancer vaccines have generated a lot of interest from oncologists since it was discovered that immune activation can lead to a specific antitumor response.1 However, despite initial progress, most cancer vaccines have failed to drive sufficient tumor immunogenicity, leading to poor clinical responses.1 The reason for this may be that previous vaccine models used inadequate ...
Manufactured by:Scancell based inOxford, UNITED KINGDOM
Modi-1 is the first vaccine based on Scancell’s Moditope® platform. The vaccine is composed of a combination of three peptides from two target antigens that are commonly modified in cancer cells. The first is the cytoskeletal protein, vimentin, which is preferentially digested during autophagy. All mesenchymal tumours such as endometrial, renal, ...
by:NEC OncoImmunity AS based inOslo, NORWAY
Recent advances in the field of immuno-oncology have established that mutated antigens (neoantigens), are viable targets of the immune system, potentially specific to each individual cancer patient. This plus many other breakthroughs in immuno-oncology and the rapid advances in next generation sequencing (NGS), opens up exciting new opportunities to harness ...
Manufactured by:Elicio Therapeutics based inBoston, MASSACHUSETTS (USA)
ELI-007 is a multivalent lymph node–targeted AMP peptide vaccine developed to target BRAF gene mutations. The BRAF gene is part of an intracellular signaling pathway that drives cell growth and division.1 BRAF mutations can lead to uncontrolled cell growth and ultimately cancer. BRAF mutations are present in multiple types of cancer, including 40% ...
Manufactured by:NeoClone based inMadison, WISCONSIN (USA)
NeoClone is a world-class custom antibody development company, having discovered hundreds of antibodies for our clients. But there are very difficult targets out there that hybridoma technology alone can't solve. So we added antibody phage display capabilities to help us develop the diverse and specific antibody repertoire to difficult targets that you need. Our team now has over 15 years of ...